Jurgenfer
insemed (Nasdaq:INSM) announced preliminary 2024 revenue results for its Arikayce property and issued 2025 revenue guidance.
Arikayce’s 2024 revenue was about $363.7 million, which exceeded the high end of the company’s guidance range, the drugmaker said. For the year 2025, INSMED (
https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186281544/image_186281544.jpg?io=getty-c-w750
Source link